Core Insights - ORIC Pharmaceuticals provided an update on the Enozertinib program during a conference call, focusing on data from an ongoing Phase Ib study in non-small cell lung cancer patients [2] Group 1: Company Updates - The conference call was led by Dominic Piscitelli, Chief Financial Officer, who welcomed participants and highlighted the recent press releases regarding updated data from the Enozertinib study [2] - The press release containing the updated data is available on the investor page of ORIC Pharmaceuticals' website [2] Group 2: Future Outlook - The company indicated that forward-looking statements would be made during the call, based on current expectations and projections about future events [3] - There is a disclaimer regarding the potential differences between actual results and those indicated by forward-looking statements, with a reference to risk factors in recent SEC filings [3]